Lord, Abbett & Co. LLC Coherus Bio Sciences, Inc. Transaction History

Lord, Abbett & Co. LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$14.42 - $21.39 $2.07 Million - $3.07 Million	-143,360 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$16.56 - $18.94 $11.7 Million - $13.4 Million	-707,125 Reduced 83.14%	143,360 $2.49 Million
Q3 2020 Nov 12, 2020	BUY	$17.41 - $19.89 $587,012 - $670,631	33,717 Added 4.13%	850,485 $15.6 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $1.8 Million - $2.4 Million	-125,013 Reduced 13.27%	816,768 $14.6 Million
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $24.9 Million - $48 Million	-2,130,459 Reduced 69.35%	941,781 $15.3 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $2.72 Million - $3.56 Million	166,776 Added 5.74%	3,072,240 $55.3 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $8.01 Million - $11.5 Million	491,126 Added 20.34%	2,905,464 $58.9 Million
Q2 2019 Aug 14, 2019	BUY	$13.1 - $22.1 $31.6 Million - $53.4 Million	2,414,338 New	2,414,338 $53.4 Million
Q3 2017 Nov 14, 2017	SELL	$11.1 - $14.5 $2.5 Million - $3.27 Million	-225,592 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	225,592	225,592 $3.24 Million

135

78M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $108M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.